Business
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today announced the presentation of the first ever preclinical data of ATNM-400 in non-small cell lung cancer (NSCLC). ATNM-400 a novel, multi-indication first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) is Actinium's lead solid tumor program, which is also being studied in prostate cancer. The data
About this update from Actinium Pharmaceuticals, Inc. (delaware)
[{"type":"text","content":"- ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO®), second line therapy Dato-DXd (Trop-2 ADC DATROWAY®) and third line therapy amivantamab (EGFR-cMET bispecific RYBREVANT®)","length":265,"tagName":"p","attribs":{}},{"type":"text","content":"- Combination of ATNM-400 and osimertinib resulted in complete tumor regression in 100% of tumor bearing animals; synergistic mechanism supported by increased ATNM-400 target antigen expression after EGFR inhibition with osimertinib","length":232,"tagName":"p","attribs":{}},{"type":"text","content":"- Improved progression free survival has been demonstrated clinically with the combination of osimertinib and external beam radiotherapy providing strong rationale for a combination with targeted alpha-therapy","length":209,"tagName":"p","attribs":{}},{"type":"text","content":"- Data validates the multi-tumor potential of ATNM-400 in multiple disease and treatment settings that support several blockbuster drugs","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Oct. 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today announced the presentation of the first ever preclinical data of ATNM-400 in non-small cell lung cancer (NSCLC). ATNM-400 a novel, multi-indication first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) is Actinium's lead solid tumor program, which is also being studied in prostate cancer. The data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics studied ATNM-400 in Epithelial Growth Factor Receptor (EGFR)-mutant NSCLC models.","length":732,"tagName":"p"},{"type":"text","content":"ATNM-400 demonstrated superior efficacy with 3-5x greater tumor growth inhibition compared to standard-of-care therapies across EGFR-mutant NSCLC including:","length":156,"tagName":"p"},{"type":"text","content":"Frontline: Osimertinib (TARGRISSO®, AstraZeneca) an EGFR tyrosine kinase inhibitor (TKI)","length":88,"tagName":"p"},{"type":"text","content":"Second line: Dato-DXd (DATROWAY®, AstraZeneca/Daiichi Sankyo) a Trop-2 antibody drug conjugate (ADC)","length...